Goldman Sachs Group Inc Curis Inc Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	BUY	$0.74 - $15.01 $52,090 - $1.06 Million	70,393 Added 52.0%	205,755 $144,000
Q3 2022 Nov 10, 2022	BUY	$0.74 - $15.01 $52,090 - $1.06 Million	70,393 Added 52.0%	205,755 $0
Q2 2022 May 14, 2024	BUY	$0.71 - $2.43 $96,107 - $328,929	135,362 New	135,362 $133,000
Q2 2022 Aug 15, 2022	SELL	$0.71 - $2.43 $283,977 - $971,922	-399,968 Reduced 74.71%	135,362 $133,000
Q1 2022 May 16, 2022	SELL	$2.31 - $5.13 $1.18 Million - $2.62 Million	-510,095 Reduced 48.79%	535,330 $1.27 Million
Q4 2021 Feb 14, 2022	SELL	$4.45 - $8.09 $1.41 Million - $2.56 Million	-315,869 Reduced 23.2%	1,045,425 $4.98 Million
Q3 2021 Nov 10, 2021	BUY	$6.94 - $8.85 $9.45 Million - $12 Million	1,361,294 New	1,361,294 $10.7 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.